Novel Therapeutic Approaches for Cutaneous Angiosarcoma, Particularly Focusing on Immune Checkpoint Inhibitors

Area of Science:

• Oncology
• Dermatology
• Cancer Research

Background:

• Cutaneous angiosarcoma (CAS) is a rare, aggressive cancer with poor prognosis.
• Systemic therapy is crucial for unresectable or metastatic CAS.
• Current treatment options have limited efficacy.

Purpose of the Study:

• To review current systemic therapies for advanced CAS.
• To discuss emerging strategies, focusing on immune checkpoint inhibitors (ICIs).

Main Methods:

• Comprehensive literature review of clinical trials, retrospective studies, and case series.
• Analysis of cytotoxic chemotherapy, targeted therapies, and ICIs.
• Focus on biomarker studies and ongoing clinical trials.

Main Results:

• Taxane-based chemotherapy (e.g., paclitaxel) is a standard option.
• Pazopanib shows modest efficacy.
• ICIs show encouraging results in specific subgroups (e.g., sun-exposed tumors with high tumor mutational burden).
• Biomarkers like TMB, PD-L1, and TILs are under investigation.
• Combination therapies (ICIs + TKIs) are being explored.

Conclusions:

• Systemic therapies for CAS have limited efficacy.
• ICIs, particularly combined with TKIs, offer a promising treatment avenue.
• Future research should focus on biomarker-driven, CAS-specific strategies.